RU2016145596A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016145596A3 RU2016145596A3 RU2016145596A RU2016145596A RU2016145596A3 RU 2016145596 A3 RU2016145596 A3 RU 2016145596A3 RU 2016145596 A RU2016145596 A RU 2016145596A RU 2016145596 A RU2016145596 A RU 2016145596A RU 2016145596 A3 RU2016145596 A3 RU 2016145596A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001188P | 2014-05-21 | 2014-05-21 | |
| US62/001,188 | 2014-05-21 | ||
| PCT/US2015/032069 WO2015179707A1 (en) | 2014-05-21 | 2015-05-21 | Imidazole derivatives as formyl peptide receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016145596A RU2016145596A (ru) | 2018-06-21 |
| RU2016145596A3 true RU2016145596A3 (enExample) | 2018-11-19 |
| RU2748652C2 RU2748652C2 (ru) | 2021-05-28 |
Family
ID=53276329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016145596A RU2748652C2 (ru) | 2014-05-21 | 2015-05-21 | Производные имидазола как модуляторы формилпептидного рецептора |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10301269B2 (enExample) |
| EP (1) | EP3145916B1 (enExample) |
| JP (1) | JP6660889B2 (enExample) |
| KR (1) | KR20170005121A (enExample) |
| CN (1) | CN106458921B (enExample) |
| AU (2) | AU2015264021B2 (enExample) |
| BR (1) | BR112016027133A8 (enExample) |
| CA (1) | CA2948876A1 (enExample) |
| DK (1) | DK3145916T3 (enExample) |
| ES (1) | ES2788700T3 (enExample) |
| RU (1) | RU2748652C2 (enExample) |
| WO (1) | WO2015179707A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| JP6196328B2 (ja) * | 2013-03-06 | 2017-09-13 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| JP6496728B2 (ja) | 2013-11-21 | 2019-04-03 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体の調節因子としてのカルバミン酸フェニル誘導体 |
| ES2788700T3 (es) | 2014-05-21 | 2020-10-22 | Allergan Inc | Derivados de imidazol como moduladores del receptor de péptido formilado |
| AU2017249047B2 (en) * | 2016-04-12 | 2021-08-05 | Allergan, Inc. | Phenyl urea derivatives as N-formyl peptide receptor modulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533210A1 (fr) | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| KR20060130064A (ko) | 2003-11-07 | 2006-12-18 | 아카디아 파마슈티칼스 인코포레이티드 | 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도 |
| PT1723128E (pt) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤 |
| AU2007287428B2 (en) * | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2009000748A1 (en) | 2007-06-27 | 2008-12-31 | Solvay Fluor Gmbh | Preparation of compounds with a perfluoroalkylsulfonyl group |
| BRPI0814818A2 (pt) * | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
| CN101998680B (zh) * | 2009-08-24 | 2016-01-13 | 中兴通讯股份有限公司 | 帧序列号的发送方法及节点b和服务无线网络控制器 |
| AU2011336973A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
| AU2012214265A1 (en) | 2011-02-11 | 2013-09-05 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| WO2013009543A1 (en) | 2011-07-11 | 2013-01-17 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| AU2012329098B2 (en) * | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| AU2013221749A1 (en) | 2012-02-16 | 2014-09-11 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators |
| SG11201406629VA (en) | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| CN110279684B (zh) | 2013-03-06 | 2023-02-28 | 阿勒根公司 | 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途 |
| JP6196328B2 (ja) | 2013-03-06 | 2017-09-13 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用 |
| US9428549B2 (en) | 2013-07-16 | 2016-08-30 | Allegran, Inc. | Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators |
| JP6496728B2 (ja) | 2013-11-21 | 2019-04-03 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体の調節因子としてのカルバミン酸フェニル誘導体 |
| US9920013B2 (en) | 2014-01-29 | 2018-03-20 | Allergan, Inc. | 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators |
| WO2015116574A1 (en) | 2014-01-29 | 2015-08-06 | Allergan, Inc. | Urea hydantoin derivatives as formyl peptide modulators |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| ES2788700T3 (es) | 2014-05-21 | 2020-10-22 | Allergan Inc | Derivados de imidazol como moduladores del receptor de péptido formilado |
| JP7032323B6 (ja) | 2016-03-28 | 2023-12-18 | アラーガン、インコーポレイテッド | Ｎ－ホルミルペプチド受容体モジュレーターとしてのフェニル尿素誘導体 |
| AU2017249047B2 (en) | 2016-04-12 | 2021-08-05 | Allergan, Inc. | Phenyl urea derivatives as N-formyl peptide receptor modulators |
-
2015
- 2015-05-21 ES ES15726498T patent/ES2788700T3/es active Active
- 2015-05-21 CA CA2948876A patent/CA2948876A1/en not_active Abandoned
- 2015-05-21 US US15/312,367 patent/US10301269B2/en active Active
- 2015-05-21 AU AU2015264021A patent/AU2015264021B2/en not_active Ceased
- 2015-05-21 JP JP2016568605A patent/JP6660889B2/ja not_active Expired - Fee Related
- 2015-05-21 RU RU2016145596A patent/RU2748652C2/ru active
- 2015-05-21 KR KR1020167035670A patent/KR20170005121A/ko not_active Ceased
- 2015-05-21 CN CN201580026983.9A patent/CN106458921B/zh active Active
- 2015-05-21 BR BR112016027133A patent/BR112016027133A8/pt not_active Application Discontinuation
- 2015-05-21 WO PCT/US2015/032069 patent/WO2015179707A1/en not_active Ceased
- 2015-05-21 EP EP15726498.7A patent/EP3145916B1/en active Active
- 2015-05-21 DK DK15726498.7T patent/DK3145916T3/da active
-
2019
- 2019-05-22 US US16/419,317 patent/US10800744B2/en active Active
-
2020
- 2020-05-25 AU AU2020203420A patent/AU2020203420B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK3145916T3 (da) | 2020-05-11 |
| AU2015264021B2 (en) | 2020-02-27 |
| BR112016027133A2 (pt) | 2017-08-15 |
| JP6660889B2 (ja) | 2020-03-11 |
| US20170096401A1 (en) | 2017-04-06 |
| RU2748652C2 (ru) | 2021-05-28 |
| US10301269B2 (en) | 2019-05-28 |
| AU2015264021A1 (en) | 2016-12-01 |
| ES2788700T3 (es) | 2020-10-22 |
| WO2015179707A1 (en) | 2015-11-26 |
| AU2020203420B2 (en) | 2021-12-16 |
| CA2948876A1 (en) | 2015-11-26 |
| CN106458921B (zh) | 2020-03-24 |
| EP3145916B1 (en) | 2020-02-12 |
| KR20170005121A (ko) | 2017-01-11 |
| EP3145916A1 (en) | 2017-03-29 |
| US20200115346A1 (en) | 2020-04-16 |
| RU2016145596A (ru) | 2018-06-21 |
| AU2020203420A1 (en) | 2020-06-11 |
| CN106458921A (zh) | 2017-02-22 |
| US10800744B2 (en) | 2020-10-13 |
| BR112016027133A8 (pt) | 2021-06-29 |
| JP2017520528A (ja) | 2017-07-27 |